micro

UBS CEO Sergio Ermotti scores points at the University of Lucerne. After his lecture, the audience is unlikely to want more regulation for banks.

Switzerland has acquired another cluster risk in addition to that of monster bank UBS. An authority is now even warning of this.

The European Court of Auditors has sharply rebuked the EU’s climate strategy. The financial auditors are giving politics a historic slap in the face.

Graubündner Kantonalbank is under pressure because of the Benko investments. A report by EY was supposed to bring salvation, but it went awry.

Travel specialist Kuoni / Dertour Suisse has shaken off the coronavirus. Despite falling travel prices, there is still reason to celebrate.

UBS has completed a share buyback and is starting a new one. However, the figures on the purchase of treasury shares reveal surprising transactions.

Galderma’s IPO has been successfully completed in Switzerland. Existing shareholders now get rid of even more shares.

The Swiss Financial Market Supervisory Authority Finma has granted an exception for UBS and Credit Suisse. This is extra ordinary.

The Ems-Chemie Group has recorded a fall in profits. But the management is responding with three clever countermeasures.

The pharmaceutical company Roche is launching a global campaign to cut hundreds of jobs. Switzerland is also affected.

A report on the demise of Credit Suisse has emerged in Bern. Explosive information has come to light, but much is to remain secret.

There are new revelations in the scandal surrounding illegal treatment methods at food giant Nestlé. The company seems completely helpless.

The pharmaceutical company Novartis has achieved a gigantic leap in profits. But the money should stay in its coffers.

The Swissbau trade fair for the construction and real estate industry attracts many visitors to Basel for its milestone anniversary. New concepts are well.

Basel-based health insurer Sympany must lay off dozens of employees. But the planned measures are unlikely to solve the cost problem.  

Investment house Vontobel has suffered a slump in profits. Costs signal a problem relative to revenues.

The Private Bank targeting the super-rich, Pictet, has performed valiantly in 2022. Notable skid marks nonetheless exist.

Swiss was hit hard by the coronavirus pandemic. But now the Swiss premium airline is taking off again with a mega business opportunity.

“Deeds not words” is the motto of retail giant Coop when it comes to environmental protection. On the 30th anniversary of its brand Naturaplan, however, the company is committing a marketing misdeed.

After the coronavirus pandemic, Roche Group nevertheless achieved stable results. This was mainly due to one circumstance.

Retailer Migros is getting bigger. This time the colossus buys a company in the medical sector and lifts the group with a liberating blow.

Reinsurer Swiss Re is surprisingly in motion. A restructuring comes to a solution that existed before.

The pharmaceutical group Novartis achieved significantly lower profits in the past financial year. It shows that you can sell silverware only once.

UBS has announced its results for the past financial year. The crux lies in the fine print, although the big bank shines above all.

Generations of schoolchildren have grown up with these products. The mastermind behind it is now withdrawing from the Swiss education market.